Journal of Clinical Pathways spoke with James Mohler, MD, about the relationship between clinical pathways and the current treatment landscape for prostate cancer (September 8-10, 2017; Washington, DC).
My name is Jim Mohler and I’m with the Roswell Park Cancer Institute.
What is the role that clinical pathways are playing in prostate cancer treatment?
We’ve had clinical pathways since the early 1990s that govern the care of inpatients primarily. Then the NCCN guidelines came about shortly thereafter, which govern the entire journey of a prostate cancer patient – from early detection all the way through treatment for potentially curative therapy and to hormonal therapy (now called androgen deprivation therapy). We now have all the new agents that confuse both physicians and patients alike because there has been so many in the last 5 years.
What do you want our participants to take away from your lecture?
I want them to understand that there is not a one-size-fits-all across the spectrum of prostate cancer. We need the right size treatment, and that’s a very complicated discussion and then a decision that has to be made by a well-educated patient.